DOI: 10.1055/s-00000025

Hormone and Metabolic Research

References

Long GV, Atkinson V, Cebon JS. et al.
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

Lancet Oncol 2017;
18: 1202-1210

Download Bibliographical Data

Access:
Access:
Access: